首页 > 最新文献

Rozhledy v Chirurgii最新文献

英文 中文
From adjustable gastric banding to Roux-en-Y gastric bypass - case report. 从可调节胃束带术到 Roux-en-Y 胃旁路术--病例报告。
Q4 Medicine Pub Date : 2024-01-01 DOI: 10.33699/PIS.2024.103.1.31-34
E Koblihová, M Kasalický, J Pažin, K Havlová, R Pohnán

Introduction: Adjustable gastric banding (AGB) used to be a popular bariatric procedure. However, it fails in more than half of those operated on in the long term, becomes ineffective and must be removed. Therefore, the use of AGB has been in decline globally. Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) are the most used bariatric revision surgeries when AGB is removed.

Case report: We present the case of a woman after AGB removal and conversion to SG who developed a stenosis of the sleeve. Therefore, a decision was made to convert to RYGB with a good effect.

Conclusion: Revisional procedures are more technically challenging than primary procedures and have higher complication rates. The most performed revisional operations include SG and RYGB. Stenosis of the sleeve can occur after SG, with a negative impact on the patient's nutritional status and quality of life. This can be managed by endoscopic dilatation, and where this solution proves ineffective, RYGB can be indicated.

导言:可调节胃束带术(AGB)曾经是一种流行的减肥手术。然而,一半以上的受术者在长期使用后会出现胃束带失效、效果不佳、必须拆除的情况。因此,胃束带术的使用在全球范围内呈下降趋势。袖带胃切除术(SG)和 Roux-en-Y 胃旁路术(RYGB)是去除 AGB 后最常用的减肥翻修手术:我们介绍了一例切除 AGB 并转为 SG 的女性病例,她的袖状胃出现狭窄。因此,决定改用 RYGB,效果良好:与初次手术相比,翻修手术在技术上更具挑战性,并发症发生率也更高。结论:与初次手术相比,翻修手术的技术难度更高,并发症发生率也更高。最常见的翻修手术包括 SG 和 RYGB。SG 术后可能会出现套管狭窄,对患者的营养状况和生活质量造成负面影响。这种情况可以通过内窥镜扩张术来解决,如果这种方法无效,则需要进行 RYGB 手术。
{"title":"From adjustable gastric banding to Roux-en-Y gastric bypass - case report.","authors":"E Koblihová, M Kasalický, J Pažin, K Havlová, R Pohnán","doi":"10.33699/PIS.2024.103.1.31-34","DOIUrl":"https://doi.org/10.33699/PIS.2024.103.1.31-34","url":null,"abstract":"<p><strong>Introduction: </strong>Adjustable gastric banding (AGB) used to be a popular bariatric procedure. However, it fails in more than half of those operated on in the long term, becomes ineffective and must be removed. Therefore, the use of AGB has been in decline globally. Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) are the most used bariatric revision surgeries when AGB is removed.</p><p><strong>Case report: </strong>We present the case of a woman after AGB removal and conversion to SG who developed a stenosis of the sleeve. Therefore, a decision was made to convert to RYGB with a good effect.</p><p><strong>Conclusion: </strong>Revisional procedures are more technically challenging than primary procedures and have higher complication rates. The most performed revisional operations include SG and RYGB. Stenosis of the sleeve can occur after SG, with a negative impact on the patient's nutritional status and quality of life. This can be managed by endoscopic dilatation, and where this solution proves ineffective, RYGB can be indicated.</p>","PeriodicalId":52413,"journal":{"name":"Rozhledy v Chirurgii","volume":"103 1","pages":"31-34"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140177709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Standardized ERAS protocol in liver and pancreatic surgery. 肝脏和胰腺手术的标准化 ERAS 方案。
Q4 Medicine Pub Date : 2024-01-01 DOI: 10.48095/ccrvch2024351
K Vinklerová, J Zajak, F Čečka, J Páral, J Sedláčková

ERAS (enhanced recovery after surgery) represents a comprehensive strategy aimed at expediting patient recovery, reducing complications, and optimizing postoperative care. The ERAS protocol encompasses recommendations for the preoperative, perioperative, and postoperative phases of patient care. Implementation of the ERAS protocol yields a multitude of benefits for both patients and the healthcare system. It shortens hospital stays, diminishes the number and severity of postoperative complications, and enhances patient's quality of life. These factors contribute to healthcare cost sav-ings and improved bed turnover efficiency. Rigorous adherence to the ERAS protocol is paramount to achieving optimal outcomes. The comprehensive ERAS strategy thus marks a paradigm shift in perioperative care and emerges as an indispensable standard in liver and pancreatic surgery.

ERAS(加强术后恢复)是一项综合策略,旨在加快患者恢复、减少并发症和优化术后护理。ERAS 方案包括术前、围术期和术后患者护理阶段的建议。ERAS 方案的实施可为患者和医疗系统带来诸多益处。它能缩短住院时间,减少术后并发症的数量和严重程度,提高病人的生活质量。这些因素都有助于节省医疗成本和提高病床周转效率。严格遵守 ERAS 方案对于取得最佳疗效至关重要。因此,ERAS综合策略标志着围手术期护理模式的转变,并成为肝脏和胰腺手术中不可或缺的标准。
{"title":"Standardized ERAS protocol in liver and pancreatic surgery.","authors":"K Vinklerová, J Zajak, F Čečka, J Páral, J Sedláčková","doi":"10.48095/ccrvch2024351","DOIUrl":"10.48095/ccrvch2024351","url":null,"abstract":"<p><p>ERAS (enhanced recovery after surgery) represents a comprehensive strategy aimed at expediting patient recovery, reducing complications, and optimizing postoperative care. The ERAS protocol encompasses recommendations for the preoperative, perioperative, and postoperative phases of patient care. Implementation of the ERAS protocol yields a multitude of benefits for both patients and the healthcare system. It shortens hospital stays, diminishes the number and severity of postoperative complications, and enhances patient's quality of life. These factors contribute to healthcare cost sav-ings and improved bed turnover efficiency. Rigorous adherence to the ERAS protocol is paramount to achieving optimal outcomes. The comprehensive ERAS strategy thus marks a paradigm shift in perioperative care and emerges as an indispensable standard in liver and pancreatic surgery.</p>","PeriodicalId":52413,"journal":{"name":"Rozhledy v Chirurgii","volume":"103 9","pages":"351-357"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142677455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complete pathological response after neoadjuvant chemotherapy and the benefit of subsequent surgery in oligometastatic pancreatic cancer patient. 少转移性胰腺癌患者新辅助化疗后的完全病理反应及后续手术的益处。
Q4 Medicine Pub Date : 2024-01-01 DOI: 10.48095/ccrvch2024454
A Langer, M Loveček, O Urban, D Kurfúrstová, R Kovář, B Mohelníková Duchoňová

Introduction: Pancreatic cancer is one of the most aggressive tumors diagnosed in local-ly advanced or metastatic stage in more than half of the cases. The standard of care is a systemic chemotherapy but the prognosis of metastatic patients remains extremely poor with a median overall survival less than one year.  However, there is increasing evidence of surgery treatment benefit in a carefully selected oligometastatic cases.  -Because oligometastatic pancreatic cancer is rare, there is a lack of robust clinical trials defining strategy, efficacy and safety of this procedure.

Patient concerns: A 77-year-old man presented with a mass in the tail of the pancreas and solitary liver metastasis. After four cycles of chemotherapy, distal pancreatectomy with liver metastasectomy was performed, and the tissues were histologically examined. The complete pathological response was found in the primary tumor and residual adenocarcinoma in liver metastasis.

Outcomes: The patient is alive without recurrency more than two years from the diagnosis.

简介:胰腺癌是最具侵袭性的肿瘤之一,超过一半的病例诊断为局部晚期或转移期。治疗的标准是全身化疗,但转移性患者的预后仍然非常差,中位总生存期不到一年。然而,越来越多的证据表明,在精心挑选的少转移病例中,手术治疗是有益的。由于少转移性胰腺癌是罕见的,缺乏强有力的临床试验来确定该手术的策略、有效性和安全性。患者关注:77岁男性,胰腺尾部有肿块,单发肝转移。化疗4个周期后,行远端胰切除术合并肝转移瘤切除术,并对组织进行组织学检查。原发肿瘤有完全的病理反应,肝转移的残余腺癌有完全的病理反应。结果:患者自诊断后存活2年以上无复发。
{"title":"Complete pathological response after neoadjuvant chemotherapy and the benefit of subsequent surgery in oligometastatic pancreatic cancer patient.","authors":"A Langer, M Loveček, O Urban, D Kurfúrstová, R Kovář, B Mohelníková Duchoňová","doi":"10.48095/ccrvch2024454","DOIUrl":"https://doi.org/10.48095/ccrvch2024454","url":null,"abstract":"<p><strong>Introduction: </strong>Pancreatic cancer is one of the most aggressive tumors diagnosed in local-ly advanced or metastatic stage in more than half of the cases. The standard of care is a systemic chemotherapy but the prognosis of metastatic patients remains extremely poor with a median overall survival less than one year.  However, there is increasing evidence of surgery treatment benefit in a carefully selected oligometastatic cases.  -Because oligometastatic pancreatic cancer is rare, there is a lack of robust clinical trials defining strategy, efficacy and safety of this procedure.</p><p><strong>Patient concerns: </strong>A 77-year-old man presented with a mass in the tail of the pancreas and solitary liver metastasis. After four cycles of chemotherapy, distal pancreatectomy with liver metastasectomy was performed, and the tissues were histologically examined. The complete pathological response was found in the primary tumor and residual adenocarcinoma in liver metastasis.</p><p><strong>Outcomes: </strong>The patient is alive without recurrency more than two years from the diagnosis.</p>","PeriodicalId":52413,"journal":{"name":"Rozhledy v Chirurgii","volume":"103 11","pages":"454-457"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perioperative systemic therapy as a part of comprehensive multimodal treatment in esophageal and gastric cancer - new treatment guidelines. 围手术期全身治疗作为食管癌和胃癌综合多模式治疗的一部分——新的治疗指南。
Q4 Medicine Pub Date : 2024-01-01 DOI: 10.48095/ccrvch2024443
R Lordick Obermannová, V Jedlička, J Dvorský, T Sokop, P Grell, M Slavik, J Trna, L Kunovský-, I Kiss

Esophageal and gastric cancer are diseases with a serious prognosis. While the incidence of gastric cancer is decreasing, the incidence of the gastroesophageal junction and esophageal cancer is increasing. Men are affected more often than women. Despite some progress in the last 10 years, cancer-specific mortality is very high, reaching 70%. The prognosis is mainly determined by the stage, histology, general condition and comorbidities. The treatment approach is curative for early and localized stages, requir-ing comprehensive care already during neoadjuvant therapy. Nutritional support is an essential part of preoperative preparation, and centres specializing in esophagogastric surgery are increasingly adopting the concept of prehabilitation. The main treatment modalities are endoscopy, surgery, systemic therapy and radiotherapy. In locally ad-vanced squamous cell carcinoma, neoadjuvant chemoradiotherapy followed by post-operative immunotherapy is the standard of care, if pathological complete remission has not been achieved. Definitive chemoradiotherapy is an alternative in patients with comorbidities. For adenocarcinoma, perioperative FLOT chemotherapy is the first choice and has shown better results than chemoradiotherapy. Chemoradiotherapy has its place in patients who would not tolerate FLOT or when trying to achieve a higher response rate. According to phase II studies, patients with MSI-high tumours could be treated with neoadjuvant immunotherapy, alone or in combination with chemotherapy; this approach has led to a pathological complete remission rate of approximately 60% and is a promising organ-preserving approach. For HER2-positive tumours, preoperative systemic therapy with trastuzumab may be considered as it demonstrates a significantly higher number of pathological complete remissions and offers the possibility of achiev-ing a higher R0 resection rate. In oligometastatic disease, surgical management of the primary tumour and metastases may be considered in individual cases in patients who respond to systemic therapy. However, an impact on overall survival has only been documented in patients with retroperitoneal involvement and no peritoneal metastases.

食管癌和胃癌是预后严重的疾病。胃癌的发病率在下降的同时,胃食管交界处和食管癌的发病率却在上升。男性比女性更容易受到影响。尽管过去10年取得了一些进展,但癌症特异性死亡率非常高,达到70%。预后主要由分期、组织学、一般情况及合并症决定。治疗方法对早期和局部阶段是可治愈的,在新辅助治疗期间需要全面的护理。营养支持是术前准备的重要组成部分,专门从事食管胃手术的中心越来越多地采用预康复的概念。主要治疗方式有内窥镜、手术、全身治疗和放射治疗。在局部晚期鳞状细胞癌中,如果病理完全缓解尚未实现,则新辅助放化疗和术后免疫治疗是标准的治疗方法。明确放化疗是合并症患者的另一种选择。对于腺癌,围手术期FLOT化疗是首选,其效果优于放化疗。放化疗在不能耐受FLOT或试图获得更高反应率的患者中有其作用。根据II期研究,msi高肿瘤患者可以单独或联合化疗接受新辅助免疫治疗;这种方法导致病理性完全缓解率约为60%,是一种有前途的器官保存方法。对于her2阳性肿瘤,可以考虑术前使用曲妥珠单抗进行全身治疗,因为它显示出更高的病理性完全缓解数量,并提供了实现更高R0切除率的可能性。在少转移性疾病中,对于对全身治疗有反应的患者,可以考虑对原发肿瘤和转移灶进行手术治疗。然而,对总生存率的影响仅在腹膜后受累且无腹膜转移的患者中有记录。
{"title":"Perioperative systemic therapy as a part of comprehensive multimodal treatment in esophageal and gastric cancer - new treatment guidelines.","authors":"R Lordick Obermannová, V Jedlička, J Dvorský, T Sokop, P Grell, M Slavik, J Trna, L Kunovský-, I Kiss","doi":"10.48095/ccrvch2024443","DOIUrl":"https://doi.org/10.48095/ccrvch2024443","url":null,"abstract":"<p><p>Esophageal and gastric cancer are diseases with a serious prognosis. While the incidence of gastric cancer is decreasing, the incidence of the gastroesophageal junction and esophageal cancer is increasing. Men are affected more often than women. Despite some progress in the last 10 years, cancer-specific mortality is very high, reaching 70%. The prognosis is mainly determined by the stage, histology, general condition and comorbidities. The treatment approach is curative for early and localized stages, requir-ing comprehensive care already during neoadjuvant therapy. Nutritional support is an essential part of preoperative preparation, and centres specializing in esophagogastric surgery are increasingly adopting the concept of prehabilitation. The main treatment modalities are endoscopy, surgery, systemic therapy and radiotherapy. In locally ad-vanced squamous cell carcinoma, neoadjuvant chemoradiotherapy followed by post-operative immunotherapy is the standard of care, if pathological complete remission has not been achieved. Definitive chemoradiotherapy is an alternative in patients with comorbidities. For adenocarcinoma, perioperative FLOT chemotherapy is the first choice and has shown better results than chemoradiotherapy. Chemoradiotherapy has its place in patients who would not tolerate FLOT or when trying to achieve a higher response rate. According to phase II studies, patients with MSI-high tumours could be treated with neoadjuvant immunotherapy, alone or in combination with chemotherapy; this approach has led to a pathological complete remission rate of approximately 60% and is a promising organ-preserving approach. For HER2-positive tumours, preoperative systemic therapy with trastuzumab may be considered as it demonstrates a significantly higher number of pathological complete remissions and offers the possibility of achiev-ing a higher R0 resection rate. In oligometastatic disease, surgical management of the primary tumour and metastases may be considered in individual cases in patients who respond to systemic therapy. However, an impact on overall survival has only been documented in patients with retroperitoneal involvement and no peritoneal metastases.</p>","PeriodicalId":52413,"journal":{"name":"Rozhledy v Chirurgii","volume":"103 11","pages":"443-453"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of perioperative chemoimmunotherapy in the treatment of potentially resectable MSI-H gastric adenocarcinoma - a case report. 围手术期化疗免疫治疗在潜在可切除的MSI-H胃腺癌治疗中的作用- 1例报告。
Q4 Medicine Pub Date : 2024-01-01 DOI: 10.48095/ccrvch2024458
T Sokop, M Kysela, F Sládek, R Lordick Obermannová

Introduction: Gastric and gastroesophageal junction adenocarcinoma is a disease with high mortality. Approximately 10% of these tumors are characterized by microsatellite instability with a presumed good response to immunotherapy. So far, treatment with checkpoint inhibitors is part of palliative regimens, in the Czech Republic this treat-ment is reimbursed in patients with MSI-H gastroesophageal adenocarcinoma exhibiting a combined positive score ≥ 5. Promising results of immunotherapy used in the early stages of MSI-H gastroesophageal adenocarcinoma were published recently.

Case report: A 59-year-old woman with locally advanced poorly cohesive MSI-H adenocarcinoma of the small curvature of the stomach. Based on the indication of the multidisciplinary team, she started neoadjuvant treatment with chemoimmunotherapy. The outcome was significant partial regression of the primary tumor and infiltrated gastric lymph nodes. Subsequently, the patient underwent uncomplicated radical total gas-trectomy with D2 lymphadenectomy. After a short postoperative recovery, she continues adjuvant treatment with immunotherapy, so far with good tolerance.

Conclusion: This case report supports the potential importance of immunotherapy in the treatment of resectable locally advanced MSI-H gastric cancer, which is currently being evaluated in clinical trials.

胃及胃食管交界处腺癌是一种高死亡率的疾病。大约10%的此类肿瘤具有微卫星不稳定性,并对免疫治疗有良好的反应。到目前为止,检查点抑制剂治疗是姑息治疗方案的一部分,在捷克共和国,这种治疗在MSI-H胃食管腺癌患者中报销,这些患者的综合阳性评分≥5。免疫治疗在早期MSI-H型胃食管腺癌中的应用取得了令人鼓舞的结果。病例报告:一名59岁的女性,患有局部晚期胃小曲度低粘连MSI-H腺癌。根据多学科小组的适应症,她开始了化疗免疫治疗的新辅助治疗。结果是原发肿瘤部分消退和胃淋巴结浸润。随后,患者行无并发症根治性全气切除术并D2淋巴结切除术。术后短暂恢复后,继续免疫治疗辅助治疗,至今耐受性良好。结论:本病例报告支持免疫治疗在可切除的局部晚期MSI-H胃癌治疗中的潜在重要性,目前正在临床试验中进行评估。
{"title":"The role of perioperative chemoimmunotherapy in the treatment of potentially resectable MSI-H gastric adenocarcinoma - a case report.","authors":"T Sokop, M Kysela, F Sládek, R Lordick Obermannová","doi":"10.48095/ccrvch2024458","DOIUrl":"https://doi.org/10.48095/ccrvch2024458","url":null,"abstract":"<p><strong>Introduction: </strong>Gastric and gastroesophageal junction adenocarcinoma is a disease with high mortality. Approximately 10% of these tumors are characterized by microsatellite instability with a presumed good response to immunotherapy. So far, treatment with checkpoint inhibitors is part of palliative regimens, in the Czech Republic this treat-ment is reimbursed in patients with MSI-H gastroesophageal adenocarcinoma exhibiting a combined positive score ≥ 5. Promising results of immunotherapy used in the early stages of MSI-H gastroesophageal adenocarcinoma were published recently.</p><p><strong>Case report: </strong>A 59-year-old woman with locally advanced poorly cohesive MSI-H adenocarcinoma of the small curvature of the stomach. Based on the indication of the multidisciplinary team, she started neoadjuvant treatment with chemoimmunotherapy. The outcome was significant partial regression of the primary tumor and infiltrated gastric lymph nodes. Subsequently, the patient underwent uncomplicated radical total gas-trectomy with D2 lymphadenectomy. After a short postoperative recovery, she continues adjuvant treatment with immunotherapy, so far with good tolerance.</p><p><strong>Conclusion: </strong>This case report supports the potential importance of immunotherapy in the treatment of resectable locally advanced MSI-H gastric cancer, which is currently being evaluated in clinical trials.</p>","PeriodicalId":52413,"journal":{"name":"Rozhledy v Chirurgii","volume":"103 11","pages":"458-461"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142792776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Borrelial pseudolymphoma of the eyebrow in an adult. 成人眉带螺旋体假性淋巴瘤。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.33699/PIS.2023.102.2.88-90
V Woznica, I Třešková

Borrelial pseudolymphoma, more commonly known as Borrelia lymphocytoma and previously also as lymphadenosis benigna cutis, is a rare manifestation of Lyme borreliosis, which occurs nearly always in children after an infection caused by Borrelia afzelii; this pathogen is transmitted exclusively by the Ixodes ricinus tick in our region. The most common body locations of this lymphocytoma include the earlobe, scrotum, nipples and the areomamillary complex. Therefore, the case of our patient was unexpected and quite rare. The aim of this article is to point out the high incidence of Lyme disease and its atypical manifestations which can be cured without surgical intervention in most cases. The authors describe the case of a 58-year-old healthy female patient with a very rare manifestation of Lyme disease.

疏螺旋体假性淋巴瘤,通常称为疏螺旋体淋巴细胞瘤,以前也称为良性皮肤淋巴结病,是莱姆性疏螺旋体病的一种罕见表现,几乎总是发生在儿童感染阿氏疏螺旋体后;这种病原体仅由我们地区的蓖麻蜱传播。这种淋巴细胞瘤最常见的身体部位包括耳垂、阴囊、乳头和乳状复合体。因此,我们的病人的情况是出乎意料的,相当罕见。本文的目的是指出莱姆病的高发和不典型的表现,在大多数情况下可以治愈而无需手术干预。作者描述了一个58岁的健康女性患者非常罕见的莱姆病的表现。
{"title":"Borrelial pseudolymphoma of the eyebrow in an adult.","authors":"V Woznica,&nbsp;I Třešková","doi":"10.33699/PIS.2023.102.2.88-90","DOIUrl":"https://doi.org/10.33699/PIS.2023.102.2.88-90","url":null,"abstract":"<p><p>Borrelial pseudolymphoma, more commonly known as Borrelia lymphocytoma and previously also as lymphadenosis benigna cutis, is a rare manifestation of Lyme borreliosis, which occurs nearly always in children after an infection caused by Borrelia afzelii; this pathogen is transmitted exclusively by the Ixodes ricinus tick in our region. The most common body locations of this lymphocytoma include the earlobe, scrotum, nipples and the areomamillary complex. Therefore, the case of our patient was unexpected and quite rare. The aim of this article is to point out the high incidence of Lyme disease and its atypical manifestations which can be cured without surgical intervention in most cases. The authors describe the case of a 58-year-old healthy female patient with a very rare manifestation of Lyme disease.</p>","PeriodicalId":52413,"journal":{"name":"Rozhledy v Chirurgii","volume":"102 2","pages":"88-90"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9828672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peroral endoscopic myotomy (POEM) in the treatment of severe postfundoplication dysphagia. 经口内窥镜下肌切开术(POEM)治疗严重缩后吞咽困难。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.33699/PIS.2023.102.5.208-213
M Vašátko, K Hugová, J Jarošová, J Špičák, J Martínek

Although uncommon, chronic postfundoplication dysphagia (PFD) is a serious complication of antireflux surgery. Currently, reoperation is the only possible solution as endoscopic pneumatic or hydraulic dilation are not effective. At present, POEM represents a standard method for the treatment of esophageal achalasia; however, in patients with PFD it is an experimental approach whose clinical effectiveness is unknown. Our case report describes a female patient who suffered from severe PFD after two surgeries (fundoplication and subsequent reoperation). Dysphagia and progressive weight loss had developed over the years and all treatment attempts (several sessions of dilation) were unsuccessful. Subsequently, esophageal resection was considered as the last resort. After a discussion in a multidisciplinary team and additional examinations (EndoFLIP), POEM was performed without any complications, and the procedure had an excellent effect without any adverse events.

虽然不常见,慢性盆腔后吞咽困难(PFD)是抗反流手术的严重并发症。目前,再手术是唯一可能的解决方案,内镜下气动或液压扩张是无效的。目前,POEM是治疗食道失弛缓症的标准方法;然而,在PFD患者中,这是一种实验性方法,其临床效果尚不清楚。我们的病例报告描述了一位女性患者,她在两次手术后患上了严重的PFD(盆底扩张和随后的再手术)。吞咽困难和进行性体重减轻已经发展多年,所有的治疗尝试(几次扩张)都不成功。随后,食管切除术被认为是最后的手段。经过多学科团队的讨论和额外的检查(EndoFLIP), POEM手术没有任何并发症,手术效果很好,没有任何不良事件。
{"title":"Peroral endoscopic myotomy (POEM) in the treatment of severe postfundoplication dysphagia.","authors":"M Vašátko,&nbsp;K Hugová,&nbsp;J Jarošová,&nbsp;J Špičák,&nbsp;J Martínek","doi":"10.33699/PIS.2023.102.5.208-213","DOIUrl":"https://doi.org/10.33699/PIS.2023.102.5.208-213","url":null,"abstract":"<p><p>Although uncommon, chronic postfundoplication dysphagia (PFD) is a serious complication of antireflux surgery. Currently, reoperation is the only possible solution as endoscopic pneumatic or hydraulic dilation are not effective. At present, POEM represents a standard method for the treatment of esophageal achalasia; however, in patients with PFD it is an experimental approach whose clinical effectiveness is unknown. Our case report describes a female patient who suffered from severe PFD after two surgeries (fundoplication and subsequent reoperation). Dysphagia and progressive weight loss had developed over the years and all treatment attempts (several sessions of dilation) were unsuccessful. Subsequently, esophageal resection was considered as the last resort. After a discussion in a multidisciplinary team and additional examinations (EndoFLIP), POEM was performed without any complications, and the procedure had an excellent effect without any adverse events.</p>","PeriodicalId":52413,"journal":{"name":"Rozhledy v Chirurgii","volume":"102 5","pages":"208-213"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9925739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Robotic pulmonary segmentectomy, initial experience in the Czech Republic. 机器人肺段切除术,在捷克共和国的初步经验。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.33699/PIS.2023.102.5.199-203
J Kolařík, J Tavandžis, R Novysedlák, J Vachtenheim, D Sibřina, M Švorcová, J Pozniak, J Šimonek, J Schützner, R Lischke

Introduction: The initiation of lung cancer screening in Czechia and diagnosis in earlier stages has been reflected by an increasing demand for anatomical lung segmentectomy. The purpose of this study was to describe early results of the first robotic-assisted thoracoscopic segmentectomies performed in the country.

Methods: Our institution has performed 151 robotic anatomical lung resections since the initiation of the screening program in August 2020, which enabled us to attain the status of a proctoring and case observation centre. The robotic segmentectomy program was initiated after completing 70 robotic lobectomies. We performed a retrospective analysis of the results of our first 20 patients indicated for robotic segmentectomy.

Results: Median age of the patients was 60, with 11 females and 7 males. The most common indications included primary lung malignancy (n=13), pulmonary metastasis (n=2) and benign lesions (n=3). We performed 11 simple segmentectomies, 6 complex (S2, S3, S1a+2, S10 on the right) and one right S6 segmentectomy with bronchoplasty. The mean number of harvested lymph nodes for NSCLC was 20, the mean blood loss was 25 mL (from 10 mL to 100 mL), and the mean operative time was 200 minutes. All resection margins were tumour-free. There was no conversion to thoracotomy. Two patients were excluded as they required conversion to robotic lobectomy given that their lesions were localized close to the intersegmental plane. One complication (recurrent laryngeal nerve paralysis) occurred in 1 patient. Mean chest tube duration was 1.9 days and length of stay 3.9 days.

Conclusion: Our experience suggests that implementation of the robotic segmentectomy program after completion of the robotic learning curve provides promising outcomes. Robotic technology and preoperative planning facilitate this technically demanding procedure especially when bronchoplasty is required.

简介:在捷克,肺癌筛查和早期诊断的开始,反映在解剖肺段切除术的需求日益增加。本研究的目的是描述在国内进行的第一次机器人辅助胸腔镜节段切除术的早期结果。方法:自2020年8月启动筛查项目以来,我院已进行了151例机器人解剖肺切除术,使我院达到了监护和病例观察中心的地位。机器人节段切除术项目是在完成70例机器人肺叶切除术后启动的。我们对前20名接受机器人节段切除术的患者的结果进行了回顾性分析。结果:患者中位年龄60岁,女性11例,男性7例。最常见的适应症包括原发性肺恶性肿瘤(13例)、肺转移(2例)和良性病变(3例)。我们进行了11例单纯节段切除术,6例复杂节段切除术(S2, S3, S1a+2,右侧S10)和1例右侧S6节段切除术合并支气管成形术。NSCLC平均淋巴结清扫数为20个,平均失血量为25 mL(从10 mL到100 mL),平均手术时间为200分钟。所有切除边缘均无肿瘤。没有转到开胸手术。2例患者被排除在外,因为他们的病变定位在靠近节段间平面的地方,需要转换为机器人肺叶切除术。1例出现喉返神经麻痹并发症。平均胸管时间1.9天,住院时间3.9天。结论:我们的经验表明,在完成机器人学习曲线后,实施机器人节段切除术计划可以提供有希望的结果。机器人技术和术前计划促进了这一技术要求很高的手术,特别是当需要支气管成形术时。
{"title":"Robotic pulmonary segmentectomy, initial experience in the Czech Republic.","authors":"J Kolařík,&nbsp;J Tavandžis,&nbsp;R Novysedlák,&nbsp;J Vachtenheim,&nbsp;D Sibřina,&nbsp;M Švorcová,&nbsp;J Pozniak,&nbsp;J Šimonek,&nbsp;J Schützner,&nbsp;R Lischke","doi":"10.33699/PIS.2023.102.5.199-203","DOIUrl":"https://doi.org/10.33699/PIS.2023.102.5.199-203","url":null,"abstract":"<p><strong>Introduction: </strong>The initiation of lung cancer screening in Czechia and diagnosis in earlier stages has been reflected by an increasing demand for anatomical lung segmentectomy. The purpose of this study was to describe early results of the first robotic-assisted thoracoscopic segmentectomies performed in the country.</p><p><strong>Methods: </strong>Our institution has performed 151 robotic anatomical lung resections since the initiation of the screening program in August 2020, which enabled us to attain the status of a proctoring and case observation centre. The robotic segmentectomy program was initiated after completing 70 robotic lobectomies. We performed a retrospective analysis of the results of our first 20 patients indicated for robotic segmentectomy.</p><p><strong>Results: </strong>Median age of the patients was 60, with 11 females and 7 males. The most common indications included primary lung malignancy (n=13), pulmonary metastasis (n=2) and benign lesions (n=3). We performed 11 simple segmentectomies, 6 complex (S2, S3, S1a+2, S10 on the right) and one right S6 segmentectomy with bronchoplasty. The mean number of harvested lymph nodes for NSCLC was 20, the mean blood loss was 25 mL (from 10 mL to 100 mL), and the mean operative time was 200 minutes. All resection margins were tumour-free. There was no conversion to thoracotomy. Two patients were excluded as they required conversion to robotic lobectomy given that their lesions were localized close to the intersegmental plane. One complication (recurrent laryngeal nerve paralysis) occurred in 1 patient. Mean chest tube duration was 1.9 days and length of stay 3.9 days.</p><p><strong>Conclusion: </strong>Our experience suggests that implementation of the robotic segmentectomy program after completion of the robotic learning curve provides promising outcomes. Robotic technology and preoperative planning facilitate this technically demanding procedure especially when bronchoplasty is required.</p>","PeriodicalId":52413,"journal":{"name":"Rozhledy v Chirurgii","volume":"102 5","pages":"199-203"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9980089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retroperitoneal tumour resection in fifteen consecutive cases: Single centre experience. 连续15例腹膜后肿瘤切除术:单中心经验。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.33699/PIS.2023.102.4.154-158
R Novotný, Z Donátová, T Büchler, J Kristek, J Froněk, L Janousek

Introduction: Retroperitoneal tumours (RTs) in adults are a rare heterogeneous group of neoplasms arising from the retroperitoneal space. RTs'clinical manifestations are nonspecific and depend on their anatomical positioning and relation with bordering structures. Our study aimed to retrospectively evaluate our patients' diagnosis, length of hospital stay, disease-free period and postoperative metastasis occurrence.

Methods: From 2011 to 2019, fifteen suspected RT resections were performed at our centre. Retrospective analysis of patients' hospital stays, follow-up, histological and immunological tumour profile, and metastasis occurrence/ re-occurrence was performed.

Result: All of the 15 (100%) patients were males. The average age of our patients was 44 years (SD ± 11.2 years), average hospital stay was 7.4 days (SD±3.4 days) (Tab.1). All resected tumours underwent histological and immunological evaluation. Based on histological examination of the resected tumours, nonseminomatous germ cell tumours were present in 12 (80%) patients - including teratoma in 4 (26.6%) patients, seminoma in 2 (13.3%) patients, and malignant B-cell lymphoma in 1 (6.6%) patient. The average patient follow-up was 42.7 months (SD±31.4.9 months). Complete remission after the surgery was achieved in 11 (76.9%) patients, and 2 (13.3%) patients were lost in follow-up.

Conclusion: RT is a rare heterogeneous group of neoplasm. The patient's prognosis dramatically depends on the type of tumour, metastasis occurrence and re-occurrence, and the surgeons' ability to resect the tumour completely.

成人腹膜后肿瘤(RTs)是一种罕见的异质性肿瘤,起源于腹膜后间隙。RTs的临床表现是非特异性的,取决于其解剖定位和与边缘结构的关系。我们的研究旨在回顾性评估我们的患者的诊断、住院时间、无病期和术后转移的发生。方法:2011年至2019年,在我中心进行了15例疑似RT切除术。回顾性分析患者住院时间、随访、肿瘤组织学和免疫学特征、转移发生/再发生情况。结果:15例患者均为男性(100%)。患者平均年龄44岁(SD±11.2年),平均住院时间7.4天(SD±3.4天)(表1)。所有切除的肿瘤都进行了组织学和免疫学评估。根据切除肿瘤的组织学检查,12例(80%)患者存在非精原细胞瘤生殖细胞肿瘤,包括4例(26.6%)畸胎瘤,2例(13.3%)精原细胞瘤,1例(6.6%)恶性b细胞淋巴瘤。患者平均随访42.7个月(SD±31.4.9个月)。11例(76.9%)患者术后完全缓解,2例(13.3%)患者失联。结论:RT是一种罕见的异质性肿瘤。患者的预后很大程度上取决于肿瘤的类型、转移的发生和再发生,以及外科医生完全切除肿瘤的能力。
{"title":"Retroperitoneal tumour resection in fifteen consecutive cases: Single centre experience.","authors":"R Novotný,&nbsp;Z Donátová,&nbsp;T Büchler,&nbsp;J Kristek,&nbsp;J Froněk,&nbsp;L Janousek","doi":"10.33699/PIS.2023.102.4.154-158","DOIUrl":"https://doi.org/10.33699/PIS.2023.102.4.154-158","url":null,"abstract":"<p><strong>Introduction: </strong>Retroperitoneal tumours (RTs) in adults are a rare heterogeneous group of neoplasms arising from the retroperitoneal space. RTs'clinical manifestations are nonspecific and depend on their anatomical positioning and relation with bordering structures. Our study aimed to retrospectively evaluate our patients' diagnosis, length of hospital stay, disease-free period and postoperative metastasis occurrence.</p><p><strong>Methods: </strong>From 2011 to 2019, fifteen suspected RT resections were performed at our centre. Retrospective analysis of patients' hospital stays, follow-up, histological and immunological tumour profile, and metastasis occurrence/ re-occurrence was performed.</p><p><strong>Result: </strong>All of the 15 (100%) patients were males. The average age of our patients was 44 years (SD ± 11.2 years), average hospital stay was 7.4 days (SD±3.4 days) (Tab.1). All resected tumours underwent histological and immunological evaluation. Based on histological examination of the resected tumours, nonseminomatous germ cell tumours were present in 12 (80%) patients - including teratoma in 4 (26.6%) patients, seminoma in 2 (13.3%) patients, and malignant B-cell lymphoma in 1 (6.6%) patient. The average patient follow-up was 42.7 months (SD±31.4.9 months). Complete remission after the surgery was achieved in 11 (76.9%) patients, and 2 (13.3%) patients were lost in follow-up.</p><p><strong>Conclusion: </strong>RT is a rare heterogeneous group of neoplasm. The patient's prognosis dramatically depends on the type of tumour, metastasis occurrence and re-occurrence, and the surgeons' ability to resect the tumour completely.</p>","PeriodicalId":52413,"journal":{"name":"Rozhledy v Chirurgii","volume":"102 4","pages":"154-158"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9675965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Robotic-assisted resection of deep pelvic schwannoma. 机器人辅助下的盆腔深部裂孔瘤切除术。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.33699/PIS.2023.102.11.437-440
M Murin, M Rousek, Š-O Schütz, T Husárová, P Vaněk, R Pohnán

Introduction: Schwannomas are a group of well differentiated benign tumors originating from the Schwann cells of the peripheral nervous system. Their localization in the pelvis is very rare. Schwannomas with expansive growth can cause wide neurologic symptoms or oppression of pelvic organs.

Case report: The authors present a case study of a 60-year-old woman with a large, symptomatic deep pelvic schwannoma. The patient underwent robotic-assisted surgery resulting in complete tumor extirpation. The patient's postoperative course was uneventful with a total of two hospitalization days. The diagnosis of a schwannoma was confirmed by histopathologic analysis. At 11-month follow-up surveillance the patient did not present any neurological deficit or other symptoms.

Conclusion: Robotic-assisted surgery allows safe and effective surgical treatment in difficult-to-access anatomical areas. Magnetic resonance imaging is required for preoperative imaging of neurogenic tumors. Histological verification is not recommended in cases where evidence of a schwannoma is found. Multidisciplinary cooperation of a dedicated team experienced in minimally invasive pelvic surgery is necessary.

简介许旺瘤是一类分化良好的良性肿瘤,起源于周围神经系统的许旺细胞。它们在骨盆中的位置非常罕见。扩张性生长的许旺瘤可引起广泛的神经症状或压迫盆腔器官:作者介绍了一例 60 岁女性的病例研究,她患有一个巨大的、有症状的盆腔深部裂孔瘤。患者接受了机器人辅助手术,肿瘤被完全切除。患者术后恢复顺利,共住院两天。经组织病理学分析,确诊为分裂瘤。在11个月的随访监测中,患者没有出现任何神经功能障碍或其他症状:结论:机器人辅助手术可以对难以进入的解剖区域进行安全有效的手术治疗。神经源性肿瘤的术前成像需要磁共振成像。在发现有分裂瘤证据的病例中,不建议进行组织学验证。有必要由一个在盆腔微创手术方面经验丰富的专业团队进行多学科合作。
{"title":"Robotic-assisted resection of deep pelvic schwannoma.","authors":"M Murin, M Rousek, Š-O Schütz, T Husárová, P Vaněk, R Pohnán","doi":"10.33699/PIS.2023.102.11.437-440","DOIUrl":"10.33699/PIS.2023.102.11.437-440","url":null,"abstract":"<p><strong>Introduction: </strong>Schwannomas are a group of well differentiated benign tumors originating from the Schwann cells of the peripheral nervous system. Their localization in the pelvis is very rare. Schwannomas with expansive growth can cause wide neurologic symptoms or oppression of pelvic organs.</p><p><strong>Case report: </strong>The authors present a case study of a 60-year-old woman with a large, symptomatic deep pelvic schwannoma. The patient underwent robotic-assisted surgery resulting in complete tumor extirpation. The patient's postoperative course was uneventful with a total of two hospitalization days. The diagnosis of a schwannoma was confirmed by histopathologic analysis. At 11-month follow-up surveillance the patient did not present any neurological deficit or other symptoms.</p><p><strong>Conclusion: </strong>Robotic-assisted surgery allows safe and effective surgical treatment in difficult-to-access anatomical areas. Magnetic resonance imaging is required for preoperative imaging of neurogenic tumors. Histological verification is not recommended in cases where evidence of a schwannoma is found. Multidisciplinary cooperation of a dedicated team experienced in minimally invasive pelvic surgery is necessary.</p>","PeriodicalId":52413,"journal":{"name":"Rozhledy v Chirurgii","volume":"102 11","pages":"437-440"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139643274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Rozhledy v Chirurgii
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1